Conference themes
The 13th World ADC London returns in 2023 as Europe's longest standing and definitive antibody-drug conjugate event - and it's back bigger and better than before!
With the recent approvals of ImmunoGen's ELAHERE, Astrazeneca and Daiichi Sankyo's DESTINY-Breast04, supporting Enhertu's use in HER2-low breast cancer as a new therapeutically targetable category, the ADC space has continued to make major waves throughout 2022, a joy to see for oncology patients around the world.
Scientific Society
Hanson Wade
Notes
Brochure: https://go.evvnt.com/1452270-3?pid=4832
Speakers: Aarti Jashnani, Principal Scientist, Bristol Myers Squibb, Abderrahman Laadem, Vice President, Global Head, Early Clinical Development, Daiichi Sankyo and more
Enquiries and Registration:
https://go.evvnt.com/1452270-2?pid=4832
Ms. Jessica Durston
CategoriesHealth Services, Public Health
